Tag «JAPAN»

Camostat Mesilate, カモスタットメシル酸塩　日局収載

Camostat Molecular FormulaC20H22N4O5 Average mass398.413 Da 4-[[4-[(Aminoiminomethyl)amino]benzoyl]oxy]benzeneacetic Acid 2-(Dimethylamino)-2-oxoethyl Ester 4-{2-[2-(Dimethylamino)-2-oxoethoxy]-2-oxoethyl}phenyl 4-carbamimidamidobenzoate 59721-28-7 [RN] Benzeneacetic acid, 4-[[4-[(aminoiminomethyl)amino]benzoyl]oxy]-, 2-(dimethylamino)-2-oxoethyl ester Camostat Mesilate カモスタットメシル酸塩　日局収載 Trypsin-like protease inhibitor CAS 59721-29-8 C20H22N4O5.CH4O3S 494.52 MP 194, methanol, diethyl ether, Chemical and Pharmaceutical Bulletin, 2005, vol. 53, 8, pg. 893 – 898 カモスタットメシル酸塩　日局収載 Camostat Mesilate Dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate monomethanesulfonate C20H22N4O5▪CH4O3S : 494.52 [59721-29-8] Launched – 1985, in Japan by Ono for the oral …

Read more

Tranilast

Tranilast Molecular FormulaC18H17NO5 Average mass327.331 Da 2-{[(2E)-3-(3,4-Dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid 3,4-DAA 5070 53902-12-8 [RN] Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s. Kissei  has developed and launched tranilast in Japan and South Korea for …

Read more

Cetilistat, セチリスタット

Cetilistat, セチリスタット Molecular FormulaC25H39NO3 Average mass401.582 Da CAS 282526-98-1 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one 282526-98-1 [RN] 2-Hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one 2-hexadecyl-oxy-6-methyl-4H-3,1-benzoxazin-4-one 4H-3,1-Benzoxazin-4-one, 2-(hexadecyloxy)-6-methyl [282526-98-1] 2-(Hexadecycloxy)-6-methyl-4H-3,1-benzoxazin-4-one ATL-962; ATL962;ATL 962 Trade Name：Oblean® MOA：Pancreatic lipase inhibitor Indication：Obesity Status：Approved, 2013-09-20 JAPAN,  Japan PMDA. Company：Norgine (Originator) , Takeda Cetilistat was approved by Pharmaceuticals Medical Devices Agency of Japan (PMDA) on September 20, 2013. It was developed by Norgine and Takeda, …

Read more

➤